Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 3/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19584987 | 0.85 | ALDH1A1 (0.51) | ALDH1A1ALDH1A3SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6224618 | 0.82 | PIK3CD (0.69) | PRKDCPIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL3480566 | 0.82 | NPC1 (0.44) | PRKDCPIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL15094202 | 0.81 | ALDH3A1 (0.56) | PRKDCPIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL1277259 | 0.81 | PRKDC (0.51) | PRKDCPIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL16577084 | 0.81 | ALDH1A1 (0.51) | PRKDCPIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL15093911 | 0.80 | LMNA (0.66) | PRKDCPIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL19212214 | 0.78 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL20424922 | 0.77 | ALDH1A1 (0.53) | PRKDCPIK3CDPIK3CBPIK3CAPIK3CG | |
| SCHEMBL21525650 | 0.77 | ALDH1A1 (0.37) | PRKDCPIK3CDPIK3CBPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149033-B2 | Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient | INSTITUT PASTEUR KOREA (KR) | 2021-10-19 | — | — | US | disclosed |
| US-20200031816-A1 | NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ST PHARM CO., LTD. (KR) | 2020-01-30 | — | — | US | disclosed |
| EP-1572693-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031816-A1 | NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ZC3HAV1, ZC3HAV1L, HAVCR2 | PRKDC 3096/4885PIK3CD 711/4885PIK3CB 1118/4885 |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | PRKDC 193/4885PIK3CD 285/4885PIK3CB 252/4885 |
| US-11149033-B2 | Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient | ZC3HAV1, ZC3HAV1L, HAVCR2 | PRKDC 2852/4885PIK3CD 922/4885PIK3CB 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.